A. Chambers

发表

Ontario cervical cancer screening clinical practice guidelines.

T. Oliver, J. Murphy, M. Fung-Kee-Fung, 2007, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Systematic review of adjuvant care for women with Stage I ovarian carcinoma

M. Carey, A. Fyles, L. Elit, 2004, Cancer.

Evidence-based Series 9-1 ARCHIVED 2013 Management of Single Brain Metastases

G. Cairncross, A. Chambers, J. Perry, 2004 .

Systematic review of management options for women with a hereditary predisposition to ovarian cancer.

J. Kwon, B. Rosen, A. Gagliardi, 2004, Gynecologic oncology.

Adjuvant Chemotherapy for Adults with Malignant Glioma: A Systematic Review

J. Cairncross, N. Laperriere, A. Chambers, 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

Kelvin K. W. Chan, M. Cheung, W. Evans, 2016, ESMO Open.

Management of Single Brain Metastases: A Clinical Practice Guideline

N. Laperriere, G. Cairncross, A. Chambers, 2006 .

Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group

N. Laperriere, D. Loblaw, A. Chambers, 2006 .

Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

M. Trudeau, M. Cheung, A. Chambers, 2019, Current oncology.

Follow-up after primary therapy for endometrial cancer: a systematic review.

T. Oliver, L. Elit, M. Fung-Kee-Fung, 2006, Gynecologic oncology.

Evidence-based Series 9-9 EDUCATION AND INFORMATION 2012 Malignant Extradural Spinal Cord Compression : Diagnosis and Management

N. Laperriere, D. Loblaw, A. Chambers, 2015 .

Malignant Extradural Spinal Cord Compression: Diagnosis and Management

N. Laperriere, A. Chambers, J. Perry, 2012 .

Surgical Management of Malignant Glioma Evidence Summary Report #9-8

A. Chambers, J. Perry, Mark R Taylor, 2004 .

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Kelvin K. W. Chan, C. de Oliveira, J. Hoch, 2020, BMJ Open.

Gliadel wafers in the treatment of malignant glioma: a systematic review

N. Laperriere, A. Chambers, J. Perry, 2007, Current oncology.

Systematic review of systemic therapy for advanced or recurrent endometrial cancer.

M. Carey, T. Oliver, M. Fung-Kee-Fung, 2006, Gynecologic oncology.

Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021

A. Chambers, S. Sehdev, 2022, Current oncology.

The impact of pricing strategy on the costs of oral anti‐cancer drugs

Kelvin K. W. Chan, M. Trudeau, M. Cheung, 2019, Cancer medicine.

The use of prophylactic anticonvulsants in patients with brain tumours—a systematic review

N. Laperriere, A. Chambers, L. Zinman, 2006, Current oncology.

Management of single brain metastasis: a practice guideline

N. Laperriere, A. Chambers, A. Mintz, 2007, Current oncology.

Screening postmenopausal women for ovarian cancer: a systematic review.

M. Johnston, M. Fung, P. Bryson, 2004, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Pan-Canadian Oncology Drug Review (pCODR): A unique model to support harmonization of cancer drug funding decisions in Canada.

M. Trudeau, A. Chambers, H. Mai, 2018, Journal of Clinical Oncology.

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise

A. Denburg, Marianne Taylor, M. Trudeau, 2021, Current oncology.

The impact of cancer drug wastage on economic evaluations

Kelvin K. W. Chan, M. Trudeau, M. Cheung, 2017, Cancer.

Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?

Kelvin K. W. Chan, M. Cheung, A. Chambers, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Chemotherapy re-challenge response rate in metastatic colorectal cancer.

T. Dragovich, R. Gerkin, A. Chambers, 2018, Journal of gastrointestinal oncology.

Engaging specialist oncologists in the assessment of oncology drugs in Canada.

Kelvin K. W. Chan, M. Cheung, W. Evans, 2017, The Lancet Oncology.

Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.

M. Fung, S. Verma, A. Chambers, 2005, Gynecologic oncology.

Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?

N. Leighl, M. Cheung, Doreen Ezeife, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence Summary Report 4-6 a EDUCATION AND INFORMATION 2014 A Quality Initiative of the Program in Evidence-based Care ( PEBC ) , Cancer Care Ontario ( CCO ) Screening Postmenopausal Women for Ovarian Cancer

M. Johnston, M. Fung, P. Bryson, 2015 .

Screening Postmenopausal Women for Ovarian Cancer

M. Johnston, M. Fung, P. Bryson, 2014 .

Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review.

J. Kwon, A. Fyles, L. Elit, 2006, Gynecologic oncology.